New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality T...
February 14 2020 - 7:05AM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular
diagnostics and precision medicine, announced that it is presenting
new data at the American Society of Clinical Oncology Genitouranary
Cancer Symposium in San Francisco, California. The key finding is
that Prolaris accurately predicts which men with intermediate or
high-risk prostate cancer will benefit from multi-modality therapy
and which can avoid unnecessary treatment.
“While it has been demonstrated that multi-modality therapy can
improve overall survival in prostate cancer, it comes at the risk
of increased morbidity and increased cost to the healthcare
system,” said Jonathan Tward M.D., PhD, associate professor in the
Department of Radiation Oncology at the University of Utah.
“Prolaris provides a unique tool that can accurately predict which
patients with high-risk prostate cancer will truly benefit from
multi-modality therapy and conversely which patients with lower
risk can safely avoid such treatments.”
The investigators evaluated 718 men with intermediate or
high-risk prostate cancer. The Prolaris score predicted metastasis
(HR=3.75; p=1.6x10-16) and remained highly predictive after
adjusting for the effect of standard clinical and pathological
features (HR=4.30; p=4.4x10-8). In the study, patients above the
high-risk threshold with a Prolaris score of greater than 2.112,
which comprised approximately 44 percent of the men in the study,
saw a statistically significant benefit from multi-modality therapy
leading to a reduction in risk of metastases. Patients below the
high-risk threshold saw no benefit from multi-modality therapy,
suggesting that such patients may be able to avoid additional
morbidity associated with additional treatment.
About Prolaris®Prolaris is a genetic test
developed by Myriad that directly measures tumor cell growth. The
Prolaris test paired with both prostate-specific antigen (PSA) and
Gleason provides the level of aggressiveness of a patient’s
individual prostate cancer. PSA and Gleason only have the ability
to identify how far the cancer has progressed thus far. However,
when these are combined with a Prolaris test score, patients get an
accurate assessment of how aggressively that cancer will progress
over the next ten years. For more information
visit: www.prolaris.com
About Myriad GeneticsMyriad
Genetics Inc. is a leading precision medicine company dedicated to
being a trusted advisor transforming patient lives worldwide with
pioneering molecular diagnostics. Myriad discovers and
commercializes molecular diagnostic tests that: determine the risk
of developing disease, accurately diagnose disease, assess the risk
of disease progression, and guide treatment decisions across six
major medical specialties where molecular diagnostics can
significantly improve patient care and lower healthcare costs.
Myriad is focused on five critical success factors: building upon a
solid hereditary cancer foundation, growing new product volume,
expanding reimbursement coverage for new products, increasing RNA
kit revenue internationally and improving profitability with
Elevate 2020. For more information on how Myriad is making a
difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice CDx, EndoPredict, Vectra, GeneSight, riskScore, Prolaris,
Foresight and Prequel are trademarks or registered trademarks of
Myriad Genetics, Inc. or its wholly owned subsidiaries in the
United States and foreign countries. MYGN-F, MYGN-G.
Lynparza is a registered trademark of AstraZeneca.
Safe Harbor StatementThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to the Company presenting new data at the
American Society of Clinical Oncology Genitouranary Cancer
Symposium in San Francisco, California; patients below the
high-risk threshold being able to avoid additional morbidity
associated with additional treatment; and the Company’s strategic
imperatives under the caption “About Myriad Genetics.” These
“forward-looking statements” are management’s present expectations
of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those described or implied in the
forward-looking statements. These risks include, but are not
limited to: the risk that sales and profit margins of the Company’s
existing molecular diagnostic tests and pharmaceutical and clinical
services may decline or will not continue to increase at historical
rates; risks related to the Company’s ability to successfully
transition from its existing product portfolio to its new tests;
risks related to changes in the governmental or private insurers’
reimbursement levels for the Company’s tests or the Company’s
ability to obtain reimbursement for its new tests at comparable
levels to its existing tests; risks related to increased
competition and the development of new competing tests and
services; the risk that the Company may be unable to develop or
achieve commercial success for additional molecular diagnostic
tests and pharmaceutical and clinical services in a timely manner,
or at all; the risk that the Company may not successfully develop
new markets for its molecular diagnostic tests and pharmaceutical
and clinical services, including the Company’s ability to
successfully generate revenue outside the United States; the risk
that licenses to the technology underlying the Company’s molecular
diagnostic tests and pharmaceutical and clinical services tests and
any future tests are terminated or cannot be maintained on
satisfactory terms; risks related to delays or other problems with
operating the Company’s laboratory testing facilities; risks
related to public concern over the Company’s genetic testing in
general or the Company’s tests in particular; risks related to
regulatory requirements or enforcement in the United States and
foreign countries and changes in the structure of the healthcare
system or healthcare payment systems; risks related to the
Company’s ability to obtain new corporate collaborations or
licenses and acquire new technologies or businesses on satisfactory
terms, if at all; risks related to the Company’s ability to
successfully integrate and derive benefits from any technologies or
businesses that it licenses or acquires; risks related to the
Company’s projections about the potential market opportunity for
the Company’s products; the risk that the Company or its licensors
may be unable to protect or that third parties will infringe the
proprietary technologies underlying the Company’s tests; the risk
of patent-infringement claims or challenges to the validity of the
Company’s patents; risks related to changes in intellectual
property laws covering the Company’s molecular diagnostic tests and
pharmaceutical and clinical services and patents or enforcement in
the United States and foreign countries, such as the Supreme Court
decisions Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S.
66 (2012), Ass’n for Molecular Pathology v. Myriad Genetics, Inc.,
569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Int’l, 573 U.S.
208 (2014); risks of new, changing and competitive technologies and
regulations in the United States and internationally; the risk that
the Company may be unable to comply with financial operating
covenants under the Company’s credit or lending agreements; the
risk that the Company will be unable to pay, when due, amounts due
under the Company’s credit or lending agreements; and other factors
discussed under the heading “Risk Factors” contained in Item 1A of
the Company’s most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, as well as any updates to those
risk factors filed from time to time in the Company’s Quarterly
Reports on Form 10-Q or Current Reports on Form 8-K.
Media Contact: |
Ron
Rogers(801) 584-3065rrogers@myriad.com |
Investor Contact: |
Scott
Gleason(801) 584-1143sgleason@myriad.com |
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2024 to May 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From May 2023 to May 2024